Apellis APLS 深 沪
已收盘 05-14 16:00:00 美东时间
41.03
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 41.03
- 总市值 525.18万
- 52周最高 41.14
- 市盈率 静 237.99
- 换手率 0.00%
- 52周最低 16.61
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 94.75
- 量 比 0
- 振 幅 0.00%
- 历史最低 11.45
- 每 手 1
- 风险率 6.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cantor Fitzgerald Suspends Neutral Rating on Apellis Pharmaceuticals
Cantor Fitzgerald suspends Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS).
05-15 20:28
Why Is Biogen Stock Falling Thursday?
Biogen shares slip after mixed Phase 2 Alzheimer's data, but analysts remain optimistic on diranersen's cognitive benefits.
05-14 23:57
美股夜盘 | Penguin Solutions Incorporation涨14.66%，Nextpower涨10.21%
Penguin Solutions Incorporation涨14.66%；Nextpower涨10.21%；Robinhood Ventures Fund I涨9.74%
05-13 10:01
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
FDA extends review for Biogen's Leqembi Iqlik for early Alzheimer's disease to August 2026.
05-08 23:31
Biogen says FDA extends review of Leqembi alzheimer’s injection
Biogen (BIIB) and Eisai (ESALF) Friday said that the FDA has extended its review by three months of the supplemental application for the Leqembi IQLIK subcutaneous injection as an initial treatment op...
05-08 14:52
Apellis Pharmaceuticals Q1 EPS $0.15 Beats $(0.36) Estimate, Sales $268.295M Beat $205.185M Estimate
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $(0.36) by 141.67 percent. This is a 120.27 percent increase over losses of $(0.74) per
05-08 05:49
Remitly Global Set To Join S&P SmallCap 600 Will Replace Apellis Pharmaceuticals
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260507-1483310/1483310_tph-apls-6.pdf
05-08 05:19
财报速睇 | Apellis制药 2026财年Q1营收2.68亿美元，同比增长60.9%；归母净利润0.19亿美元，扭亏为盈
华盛资讯5月7日讯，Apellis制药公布2026财年Q1业绩，公司Q1营收2.68亿美元，同比增长60.9%，归母净利润0.19亿美元，扭亏为盈。
05-07 19:23
Apellis Q1 FY26 swings to net income of $18.66 million; revenue rises 61% to $268.3 million
Apellis Q1 FY26 swings to net income of $18.66 million; revenue rises 61% to $268.3 million Apellis Pharmaceuticals swung to net income of USD 18.66 million as revenue climbed 61% to USD 268.3 million. Net product revenue rose 28% to USD 192.01 million, led by SYFOVRE at USD 150.7 million and EMPAVE
05-07 18:57
渤健下调2026年盈利预期
渤健预计全年营收较 2025 年的 98.9 亿美元出现中个位数百分比下滑 渤健下调 2026 年盈利指引，并预期全年营收走弱。 尽管一季度销售额...
04-29 21:22
